Interpreting clinical trials in lung cancer

Impact of methodology and endpoints

Richard J. Gralla, Frank Griesinger

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The design and analysis of clinical trials are crucial if we are confidently to answer important questions regarding the treatment of patients with non-small cell lung cancer. Survival, response, and quality of life (QoL) are considered the key endpoints of oncology clinical trials. Survival is the primary endpoint of most randomized, phase III clinical trials, but small improvements in survival are difficult to detect without a sufficiently large sample size. Meta-analysis is a useful technique to increase statistical precision and better estimate the magnitude of a treatment effect. Although survival data guide treatment choice, the objective response is generally the parameter used to evaluate treatment in the clinic, despite its inherent unreliability. The objective response rate remains an important outcome for early phase clinical trials. QoL, which is a particularly important trial endpoint if survival differences are unlikely may, however, be a more relevant outcome in the clinic. Several validated QoL tools are available for use both in trials and in daily practice, but many clinicians do not routinely assess QoL when evaluating an individual patient's response to treatment. Recent advances in electronic technology make capturing QoL data at each office visit not only possible but practical, reliable, and useful for both patients and clinicians. Therefore, although survival, response, and QoL can all be relevant clinical trial endpoints, QoL may be the most relevant endpoint to assess in the clinic.

Original languageEnglish (US)
JournalJournal of Thoracic Oncology
Volume2
Issue numberSUPPL. 2
DOIs
StatePublished - 2007
Externally publishedYes

Fingerprint

Lung Neoplasms
Quality of Life
Clinical Trials
Survival
Therapeutics
Office Visits
Phase III Clinical Trials
Non-Small Cell Lung Carcinoma
Sample Size
Meta-Analysis
Technology

Keywords

  • Docetaxel
  • Endpoints
  • Non-small cell lung cancer
  • Quality of life
  • Response
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Interpreting clinical trials in lung cancer : Impact of methodology and endpoints. / Gralla, Richard J.; Griesinger, Frank.

In: Journal of Thoracic Oncology, Vol. 2, No. SUPPL. 2, 2007.

Research output: Contribution to journalArticle

@article{7d64c91290ae4b5582f9596652925548,
title = "Interpreting clinical trials in lung cancer: Impact of methodology and endpoints",
abstract = "The design and analysis of clinical trials are crucial if we are confidently to answer important questions regarding the treatment of patients with non-small cell lung cancer. Survival, response, and quality of life (QoL) are considered the key endpoints of oncology clinical trials. Survival is the primary endpoint of most randomized, phase III clinical trials, but small improvements in survival are difficult to detect without a sufficiently large sample size. Meta-analysis is a useful technique to increase statistical precision and better estimate the magnitude of a treatment effect. Although survival data guide treatment choice, the objective response is generally the parameter used to evaluate treatment in the clinic, despite its inherent unreliability. The objective response rate remains an important outcome for early phase clinical trials. QoL, which is a particularly important trial endpoint if survival differences are unlikely may, however, be a more relevant outcome in the clinic. Several validated QoL tools are available for use both in trials and in daily practice, but many clinicians do not routinely assess QoL when evaluating an individual patient's response to treatment. Recent advances in electronic technology make capturing QoL data at each office visit not only possible but practical, reliable, and useful for both patients and clinicians. Therefore, although survival, response, and QoL can all be relevant clinical trial endpoints, QoL may be the most relevant endpoint to assess in the clinic.",
keywords = "Docetaxel, Endpoints, Non-small cell lung cancer, Quality of life, Response, Survival",
author = "Gralla, {Richard J.} and Frank Griesinger",
year = "2007",
doi = "10.1097/01.JTO.0000269734.27047.3e",
language = "English (US)",
volume = "2",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Interpreting clinical trials in lung cancer

T2 - Impact of methodology and endpoints

AU - Gralla, Richard J.

AU - Griesinger, Frank

PY - 2007

Y1 - 2007

N2 - The design and analysis of clinical trials are crucial if we are confidently to answer important questions regarding the treatment of patients with non-small cell lung cancer. Survival, response, and quality of life (QoL) are considered the key endpoints of oncology clinical trials. Survival is the primary endpoint of most randomized, phase III clinical trials, but small improvements in survival are difficult to detect without a sufficiently large sample size. Meta-analysis is a useful technique to increase statistical precision and better estimate the magnitude of a treatment effect. Although survival data guide treatment choice, the objective response is generally the parameter used to evaluate treatment in the clinic, despite its inherent unreliability. The objective response rate remains an important outcome for early phase clinical trials. QoL, which is a particularly important trial endpoint if survival differences are unlikely may, however, be a more relevant outcome in the clinic. Several validated QoL tools are available for use both in trials and in daily practice, but many clinicians do not routinely assess QoL when evaluating an individual patient's response to treatment. Recent advances in electronic technology make capturing QoL data at each office visit not only possible but practical, reliable, and useful for both patients and clinicians. Therefore, although survival, response, and QoL can all be relevant clinical trial endpoints, QoL may be the most relevant endpoint to assess in the clinic.

AB - The design and analysis of clinical trials are crucial if we are confidently to answer important questions regarding the treatment of patients with non-small cell lung cancer. Survival, response, and quality of life (QoL) are considered the key endpoints of oncology clinical trials. Survival is the primary endpoint of most randomized, phase III clinical trials, but small improvements in survival are difficult to detect without a sufficiently large sample size. Meta-analysis is a useful technique to increase statistical precision and better estimate the magnitude of a treatment effect. Although survival data guide treatment choice, the objective response is generally the parameter used to evaluate treatment in the clinic, despite its inherent unreliability. The objective response rate remains an important outcome for early phase clinical trials. QoL, which is a particularly important trial endpoint if survival differences are unlikely may, however, be a more relevant outcome in the clinic. Several validated QoL tools are available for use both in trials and in daily practice, but many clinicians do not routinely assess QoL when evaluating an individual patient's response to treatment. Recent advances in electronic technology make capturing QoL data at each office visit not only possible but practical, reliable, and useful for both patients and clinicians. Therefore, although survival, response, and QoL can all be relevant clinical trial endpoints, QoL may be the most relevant endpoint to assess in the clinic.

KW - Docetaxel

KW - Endpoints

KW - Non-small cell lung cancer

KW - Quality of life

KW - Response

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=34250796275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250796275&partnerID=8YFLogxK

U2 - 10.1097/01.JTO.0000269734.27047.3e

DO - 10.1097/01.JTO.0000269734.27047.3e

M3 - Article

VL - 2

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - SUPPL. 2

ER -